Kearns-Sayre syndrome

March 23, 2015June 1, 2015

Raptor Pharmaceuticals’ Experimental Therapy in Phase 2 / 3 Trial for Leigh Syndrome

Raptor Pharmaceuticals Inc. is looking to bring relief to a wide variety of young patients with inherited mitochondrial disease through its therapeutic called RP103 (cysteamine bitartrate delayed-release capsules). A Phase ... Read more

March 11, 2015June 1, 2015

Early Folinic Acid Supplementation Improves Symptoms of Kearns-Sayre Syndrome

Kearns-Sayre syndrome

If patients with Kearns-Sayre syndrome commonly are deficient in folate, logic would presume folinic acid therapy may benefit their symptoms. A team from Spain tested this theory in the article ... Read more

March 2, 2015June 1, 2015

Procedure Corrects Kearns-Sayre Syndrome Eyelid Drooping

Kearns-Sayre syndrome

Chronic progressive external ophthalmoplegia (CPEO) is the most common characteristic of Kearns-Sayre syndrome, which is one member of the family of mitochondrial myopathies. Patients with CPEO may benefit from bilateral ... Read more

February 24, 2015June 1, 2015

Novel Therapy for Multiple Mitochondrial Diseases Now in Clinical Trials

Friedreich's Ataxia, Kearns-Sayre syndrome, Leigh syndrome

Edison Pharmaceuticals is actively engaged in a number of phase 2 clinical trials investigating their drug candidate EPI-743 in a variety of mitochondrial respiratory chain diseases. The studies range from ... Read more